Rhabdomyolysis: a Case Study Exploring the Possible Side Effect of Lipid Lowering Medication by a HIV Positive Patient Taking a Protease Inhibitor

Overview

Journal J Can Chiropr Assoc

Date 2008 Dec 11

PMID 19066698

Citations 3

Authors

Diana De Carvalho

Mark Citro

Anthony Tibbles

Affiliations

Soon will be listed here.

Abstract

This case study explores the incidence of rhabdomyolysis in a HIV positive patient that was taking a lipid lowering drug and a protease inhibitor concurrently while under chiropractic treatment for generalized muscular soreness. Dyslipidemia is a very common problem both in the general and HIV population, with many patients being prescribed lipid lowering drugs. While extremely rare, adverse effects of lipid lowering drugs have been documented to include myopathy such as rhabdomyolysis. It is imperative that chiropractors are aware of the possible adverse side effect of lipid lowering drug therapy in their patients complaining of musculoskeletal pain. It is even more important that chiropractors treating the HIV population are aware of the potential interactions between these medications and protease inhibitors to cause myopathy.

Citing Articles

Adrenal Insufficiency and Mild Rhabdomyolysis Revealing a Human Immunodeficiency Virus Infection: A Case Report.

Haddiya I, Berkhli H, Hamaz S, Bentata Y Saudi J Med Med Sci. 2019; 4(3):212-214.

PMID: 30787732 PMC: 6298355. DOI: 10.4103/1658-631X.188262.

The prevalence and characteristics of HIV/AIDS patients presenting at a chiropractic outpatient clinic in Toronto, Ontario. A retrospective, observational study.

Injeyan H, Connell G, Foster K, Kopansky-Giles D, Sovak G, Tibbles T J Can Chiropr Assoc. 2018; 62(2):77-84.

PMID: 30305763 PMC: 6173221.

Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients.

Rodine R, Tibbles A, Kim P, Alikhan N J Can Chiropr Assoc. 2010; 54(1):43-51.

PMID: 20195425 PMC: 2829685.

References

Vanholder R, Sever M, Erek E, Lameire N . Rhabdomyolysis. J Am Soc Nephrol. 2000; 11(8):1553-1561. DOI: 10.1681/ASN.V1181553. View

Schoonjans K, Martin G, Staels B, Auwerx J . Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997; 8(3):159-66. DOI: 10.1097/00041433-199706000-00006. View

Grunfeld C, Kotler D, Shigenaga J, Doerrler W, Tierney A, Wang J . Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991; 90(2):154-62. View

Adkins J, Faulds D . Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997; 54(4):615-33. DOI: 10.2165/00003495-199754040-00007. View

Rupert S . Pathogenesis and treatment of rhabdomyolysis. J Am Acad Nurse Pract. 2002; 14(2):82-7. DOI: 10.1111/j.1745-7599.2002.tb00095.x. View

Barker B, Goodenough R, Falko J . Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care. 2003; 26(8):2482-3. DOI: 10.2337/diacare.26.8.2482. View

Dube M, Stein J, Aberg J, Fichtenbaum C, Gerber J, Tashima K . Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the.... Clin Infect Dis. 2003; 37(5):613-27. DOI: 10.1086/378131. View

Sellmeyer D, Grunfeld C . Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev. 1996; 17(5):518-32. DOI: 10.1210/edrv-17-5-518. View

Penzak S, Chuck S . Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis. 2000; 32(2):111-23. DOI: 10.1080/003655400750045196. View

10.

Solano M, Goldberg R . Management of dyslipidemia in diabetes. Cardiol Rev. 2006; 14(3):125-35. DOI: 10.1097/01.crd.0000188034.76283.5e. View

11.

Tsiodras S, Mantzoros C, Hammer S, Samore M . Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000; 160(13):2050-6. DOI: 10.1001/archinte.160.13.2050. View

12.

Grunfeld C, Pang M, Doerrler W, Shigenaga J, Jensen P, Feingold K . Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992; 74(5):1045-52. DOI: 10.1210/jcem.74.5.1373735. View

13.

Furler M, Einarson T, Walmsley S, Millson M, Bendayan R . Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. AIDS Patient Care STDS. 2003; 17(4):155-68. DOI: 10.1089/108729103321619764. View

14.

Tugwood J, Issemann I, Anderson R, Bundell K, McPheat W, Green S . The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992; 11(2):433-9. PMC: 556472. DOI: 10.1002/j.1460-2075.1992.tb05072.x. View

15.

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm D . A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998; 12(7):F51-8. DOI: 10.1097/00002030-199807000-00003. View

16.

Sauret J, Marinides G, Wang G . Rhabdomyolysis. Am Fam Physician. 2002; 65(5):907-12. View

17.

Clouatre Y, LeBlanc M, Ouimet D, Pichette V . Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant. 1999; 14(4):1047-8. DOI: 10.1093/ndt/14.4.1047. View

18.

Warren J, Blumbergs P, Thompson P . Rhabdomyolysis: a review. Muscle Nerve. 2002; 25(3):332-47. DOI: 10.1002/mus.10053. View

19.

Mooser V, Carr A . Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol. 2001; 12(3):313-9. DOI: 10.1097/00041433-200106000-00011. View

20.

Omar M, Wilson J, Cox T . Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001; 35(9):1096-107. DOI: 10.1345/aph.10228. View